2 results
Approved WMOCompleted
Primary:To evaluate the feasibility and safety of intra-tumour and peri-tumour therapy with GMP hBMP4 in increasing doses in patients with progressive and/or multiple recurrent GBM, identify DLT, and to determine whether there is a maximum tolerated…
Approved WMOPending
The objectives of this are to establish the safety, tolerability, and preliminary efficacy of VRDN-001, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of VRDN-001 in NHV and TED patients over a dose range of 3.0 to 20.0 mg/kg.